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ABSTRACT
Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally
considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated cell
surface HLA class I, HLA class II and cytoplasmic HLA-DM staining by immunohistochemistry (IHC) in 389
classical Hodgkin lymphomas (cHL), 22 nodular lymphocyte predominant Hodgkin lymphomas (NLPHL),
137 diffuse large B-cell lymphomas (DLBCL), 39 primary central nervous system lymphomas (PCNSL) and
19 testicular lymphomas. We describe a novel mechanism of immune escape in which loss of HLA-DM
expression results in aberrant membranous invariant chain peptide (CLIP) expression in HLA class II cell
surface positive lymphoma cells, preventing presentation of antigenic peptides. In HLA class II positive
cases, HLA-DM expression was lost in 49% of cHL, 0% of NLPHL, 14% of DLBCL, 3% of PCNSL and 0% of
testicular lymphomas. Considering HLA class I, HLA class II and HLA-DM together, 88% of cHL, 10% of
NLPHL, 62% of DLBCL, 77% of PCNSL and 87% of testicular lymphoma cases had abnormal HLA expression
patterns. In conclusion, an HLA expression pattern incompatible with normal antigen presentation is
common in cHL, DLBCL, PCNSL and testicular lymphoma. Retention of CLIP in HLA class II caused by loss
of HLA-DM is a novel immune escape mechanism, especially prevalent in cHL. Aberrant HLA expression













In the past decade, cancer immunotherapy has made major
advances by targeting a series of cell surface molecules
known as immune checkpoints. The checkpoint molecules
can repress the function of killer and pro-inﬂammatory
lymphocytes. Checkpoint inhibitors are monoclonal antibod-
ies (mAbs) that block these inhibitory receptors, thereby
stimulating T-cells and generating an antitumor response.1-3
B-cell lymphoma comprise a heterogeneous group of malig-
nancies, which arise from malignant transformation of
B-cells. The mAbs against programmed death 1 (PD-1) and
cytotoxic T-lymphocyte antigen 4 (CTLA-4) have shown
substantial therapeutic activity in heavily treated classical
Hodgkin lymphoma (cHL) and encouraging results in
relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
with overall response rates (ORR) of 87% and 36% respec-
tively.4-8 Despite these encouraging results, complete
remissions are rare and it remains to be established which
patients beneﬁt most from checkpoint inhibition.
Antigen presentation depends on the proper processing of
proteins and presentation of peptides through the human leu-
kocyte antigens (HLA).9 Normal B-cells present antigens
through HLA class I, like any other nucleated cell, and as pro-
fessional antigen-processing cells also in the context of HLA
class II.10,11 In cancer cells, so called neo-antigens can arise
from proteins that are altered, e.g. by gene mutations. Presenta-
tion of these neo-antigens by HLA should induce antitumor
immune responses. However, lymphoma cells can prevent
these responses by various immune evasive mechanisms,
including expression of immune checkpoint molecules.12,13
Another mechanism to prevent antitumor immune responses
involves loss or aberrant expression of HLA, which precludes
presentation of tumor cell speciﬁc antigens. Thus, loss or aber-
rant HLA expression may very well have an impact on the efﬁ-
cacy of checkpoint inhibitors.
Loss of membranous HLA class I and/or HLA class II
expression has frequently been described in B-cell lymphomas,
including cHL, DLBCL, primary mediastinal B-cell lymphoma
CONTACT Dr. Arjan Diepstra a.diepstra@umcg.nl Department of Pathology and Medical Biology, University Medical Centre Groningen, Hanzeplein 1, PO Box
30.001, 9700RB Groningen, the Netherlands.
Supplemental data for this article can be accessed on the publisher’s website.
Presented as an oral at the American Society of Hematology (ASH) lymphoma biology meeting in Colorado Springs, 20th of June 2016. Part of this work was also pre-
sented as an oral at the 10th International Symposium on Hodgkin lymphoma in Cologne, Germany, 24th October 2016 and was awarded the Karl Musshoff award (best
basic abstract).
Published with license by Taylor & Francis Group, LLC © Marcel Nijland, Rianne N. Veenstra, Lydia Visser, Chuanhui Xu, Kushi Kushekhar, Gustaaf W. van Imhoff, Philip M. Kluin, Anke van den
Berg, and Arjan Diepstra.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
ONCOIMMUNOLOGY
2017, VOL. 6, NO. 4, e1295202 (8 pages)
http://dx.doi.org/10.1080/2162402X.2017.1295202
(PMBCL) and the immune privileged aggressive B-cell lym-
phomas of brain and testis.14-27 Observations in several B-cell
non-Hodgkin lymphomas (NHL) indicate cytoplasmic reten-
tion of HLA-molecules in a proportion of patients.17,20,25,27,28
In three cHL lymph node cell suspensions, it has been
described that disruption of antigen presentation is caused by
retention of the class II-associated invariant chain peptide
(CLIP) in the membranous HLA class II molecules.16
HLA-DM is essential in the intracellular assembly of HLA
class II-antigenic peptide complexes. It displaces CLIP from
the antigen binding groove of HLA class II molecules, to
make this groove accessible for loading of antigens. Lack of
HLA-DM results in an apparently normal cell surface expres-
sion of HLA class II, but without presentation of antigens and
neo-antigens.9 In this study, we examined the combined pro-
tein expression patterns of HLA class I and HLA class II in a
large set of cHL, nodular lymphocyte predominant Hodgkin
lymphoma (NLPHL), DLBCL, primary central nervous system
lymphoma (PCNSL) and primary testicular lymphoma. We
expanded this with HLA-DM as well as CLIP in a subset of
patients to determine whether the lymphoma cells apply this
alternative mechanism of inducing functional loss of HLA
class II antigen presentation.
Results
HLA expression in cHL
Of the 389 cHL samples, 28 were not evaluable for HLA class
I and/or HLA class II and were excluded from further analy-
sis. Normal HLA class I cell surface expression was observed
in tumor cells in 132 out of 361 cases (36.6%), signiﬁcantly
more often in EBVCcHL (72.6%) than in EBV-cHL (16.8%)
(p < 0.001). Various aberrant staining patterns were
observed, including complete lack of both B2M and HC10 in
52.8% of negative cases (Fig. 1). Of the HLA class I negative
cases 38.1% had only cytoplasmic B2M staining and in 8.3%
only cytoplasmic HC10 staining. Cell surface expression of
HLA class II was present in 214 out of 361 cHL cases
(59.3%), signiﬁcantly more often in EBVCcHL (70.3%) than
Figure 1. Immunohistochemical staining patterns in formalin ﬁxed parafﬁn embedded classical Hodgkin lymphoma tissue for HLA class I, B2M and HLA class II. (A and B)
negative and positive membranous staining for HLA class I heavy chains. (C and D) negative and positive membranous staining for B2M. (E and F) negative and positive
membranous staining for HLA class II. 40x.
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in EBV-cHL (53.2%) (p < 0.001) (Table 1). In 40.1% of the
HLA class II cell surface negative cases cytoplasmic staining
was observed.
CLIP and HLA-DM expression in cHL
Twenty HLA class II membrane positive cases, for which frozen
material was available, were stained for CLIP and HLA-DM.
CLIP staining was clearly membranous in eight cases, indicat-
ing diminishment or lack of presentation of immunogenic pep-
tides in the context of HLA class II. In all of these eight cases
HLA-DM staining was completely negative, both in frozen and
corresponding formalin-ﬁxed parafﬁn-embedded (FFPE) tis-
sue. In the 12 cases with normal CLIP staining (weak cyto-
plasmic), HLA-DM was expressed (Fig. 2). HLA-DM staining
was then performed on an additional 69 HLA class II positive
FFPE cases. In total, HLA-DM expression was lacking in 44 out
of 89 cases of cHL (49.4%).
HLA expression in NLPHL
Of the 22 NLPHL cases, 1 was not evaluable for HLA class II
and was excluded from further analysis. The majority of cases
(90.5%) had normal HLA class I and HLA class II expression.
Loss of HLA class II was observed in one case and combined
loss of HLA class I and class II in another case. None of the
HLA class II positive cases had HLA-DM loss.
HLA expression patterns in DLBCL
Of the 137 DLBCL samples, 20 were not evaluable for either
HLA class I, HLA class II or HLA-DM and were excluded from
further analysis. HLA class I surface expression was observed
in 53 out of 117 cases (45.3%) (Table 2). Of the HLA class I
membrane negative cases, two showed cytoplasmic HC10 stain-
ing. Cytoplasmic B2M was detected in 31 of the 64 (48.4%)
HLA class I negative cases, these did not include the two HC10
cytoplasmic staining cases. Cell surface HLA class II expression
was observed in 78 out of 117 DLBCL cases (66.7%). Of the
negative membrane cases, cytoplasmic HLA class II expression
was seen in 10 out of 39 (25.6%). We found that in the 78 HLA
class II cell surface expressing tumor cells, HLA-DM expression
was lacking in 11 cases (14.1%). Representative examples of the
various staining patterns observed for HC10, B2M and HLA
class II are shown in Fig. 2.
HLA-expression patterns in PCNSL and testicular
lymphoma
Of the 39 PNCSL samples, 5 were not evaluable for either HLA
class I, HLA class II or HLA-DM and were excluded from
Table 1. HLA class I, HLA class II and HLA-DM staining patterns in tumor cells of
361 classical Hodgkin lymphoma patients.
HLA Hodgkin
I II DM Total % EBVC % EBV¡ %
(n D 361) (n D 128) (n D 233) p value
C C C 12.4 27.7 4.1 < 0.01
C ¡ ND 11.1 15.6 8.6 0.11
C C ¡ 13.0 29.3 4.1 < 0.01
¡ C C 17.6 3.8 25.4 < 0.01
¡ ¡ ND 29.7 14.1 38.2 < 0.01
¡ C ¡ 16.2 9.5 19.6 0.03
ND indicates not done.
Figure 2. CLIP and HLA-DM immunohistochemistry in frozen classical Hodgkin lymphoma tissue from two representative patients. (A) aberrant membranous CLIP staining
in (B) the absence of HLA-DM. (C) normal absence of membranous CLIP staining in (D) presence of cytoplasmic HLA-DM staining. Circles indicate tumor cells. 40x.
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further analysis. HLA class I and HLA class II cell surface
expression was observed in 29.4% of cases, whereas there was a
loss of HLA class I and HLA class II in 24 out of 34 (70.6%)
and 19 out of 34 (55.9%) cases, respectively (Table 2). HLA-
DM loss was observed in 1 case (2.9%). Of the 19 primary tes-
ticular lymphoma, 4 were excluded because of missing staining
data. Two samples (13.3%) showed normal HLA expression,
while 12 samples (80%) lacked both HLA class I and HLA class
II (Table 2)
Combined expression patterns in cHL, NLPHL, DLBCL,
PCNSL and testicular lymphoma
Combined results of functional cell surface HLA class I and II
expression are presented in Table 3. These combined analyses
show that only 12.4% of cHL, 37.6% of DLBCL, 23.5% of
PCNSL and 13.3% of testicular lymphoma show an HLA
expression pattern that is compatible with normal antigen pre-
sentation. In contrast, 90.5% of NLPHL cases show normal
HLA class I and HLA class II expression.
In EBV-cHL the most prevalent pattern is the combined loss
of HLA class I and HLA class II, whereas in EBVCcHL there is
more often disruption of HLA class II signaling, either through
HLA class II or HLA-DM loss (Table 1).
In DLBCL the most frequent aberrant HLA expression is the
loss of both HLA class I and HLA class II (35%). Isolated HLA
class I loss (19.7%) is more common than isolated loss of HLA
class II and HLA-DM (7.7% and 4.3%) (Tables 2 and 3). The
HLA expression patterns were not related to gender, age or
stage of the disease (Table S1). In the cohort of patients treated
with R-CHOP, we observed no signiﬁcant difference in pro-
gression free survival (PFS) between patients with a normal
HLA pattern or aberrant HLA pattern (Log Rank p value 0.25)
(Fig. S1).
PCNSL and testicular lymphoma have the highest frequency
of combined HLA class I and HLA class II loss (52.9% and
80%), with isolated loss of HLA class I or HLA II only being
observed incidentally. HLA-DM loss does not seem to consti-
tute a recurrent mechanism for immune escape in either
PCNSL or primary testicular lymphoma.
Discussion
As proper antigen presentation in the context of HLA is
expected to be a prerequisite for the action of immune check-
point inhibitors, we studied HLA expression in retrospective
cohorts of B-cell lymphoma. We showed that only a minority
of cHL, DLBCL, PNCSL and testicular lymphoma cases show
HLA expression that is compatible with normal antigen presen-
tation for both HLA class I and II. Combined HLA class I and
HLA class II loss was the most prevalent aberrant pattern in all
these lymphoma. In cHL and DLBCL, we identiﬁed loss of
HLA-DM as a novel mechanism causing disruption of normal
antigen presentation in the context of HLA class II.
The minimal requirement for B-cell lymphoma tumor cells
to act like professional antigen presenting cells is cell surface
expression of the HLA class I heavy chain-B2M complex and
the HLA class II heavy chain dimer. Immunohistochemistry
(IHC) for these components in normal germinal center B-cells
shows strong membranous staining and weak cytoplasmic
staining. In EBV-cHL, HLA class I expression has previously
been reported to be lacking in 55% (n D 38), 81% (n D 21) and
71% (n D 14) of cases 29-31 while, we found 83.2% (n D 233). In
EBVCcHL these percentages are much lower: 8% (n D 25),
24% (n D 17), 25% (n D 24) and in our series loss of HLA class
I was observed in 27.4% (n D 128).
In previous publications on DLBCL a wide range of HLA
class I loss has been reported, ranging from 34% to 75%,19-22
compared with 54.7% in our study. The lower values in this
range correspond to studies that made no distinction between
membranous and cytoplasmic staining in IHC. Loss of HLA
class II expression is consistently less frequently reported than
HLA class I loss.24-27 Importantly, in the majority of these stud-
ies no aberrant cytoplasmic HLA class II staining was described
and probably included as positive. In a recent study, speciﬁcally
looking at cytoplasmic HLA class II expression, aberrant
expression patterns were observed in 41%. Interestingly, aber-
rant HLA class II expression was more often observed in the
non-germinal center B-cell type.28 Taking this into account, as
well as differences in methodology and antibodies used, the
results of these studies are compatible with our observed loss of
membranous HLA class II expression in 33.3% of cases.
Our IHC results indicate that there is a variety of mecha-
nisms involved in the lack of cell surface HLA expression, judg-
ing from different staining patterns in the cytoplasm (absent,
diffuse, granular or with Golgi-like localization). In PCNSL and
primary testicular lymphoma, loss of HLA-I and HLA-II is fre-
quently due to homozygous or heterozygous deletions of the
Table 2. HLA class I, HLA class II and HLA-DM tumor cell staining patterns in 117
diffuse large B-cell lymphoma, 34 primary central nervous system lymphoma and
15 primary testicular lymphoma patients.
HLA
DLBCL% PCNSL% Testicular%
I II DM (n D 117) (n D 34) (n D 15)
C C C 37.6 23.5 13.3
C ¡ ND 3.4 5.9 6.7
C C ¡ 4.3 0 0
¡ C C 19.7 17.7 0
¡ ¡ ND 29.9 50.0 80
¡ C ¡ 5.1 2.9 0
ND indicates not done.
Table 3. Functional deﬁcits in antigen presentation in tumor cells of classical














“Normal” 12.4 90.4 37.6 23.5 13.3
HLA class I dysfunction 17.6 4.8 19.7 17.7 0
HLA class II dysfunction 24.1 0 7.7 5.9 6.7
HLA class I and II
dysfunction
45.9 4.8 35.0 52.9 80
Notes: Membraneous expression of HLA class I and class II with cytoplasmic HLA-
DM. HLA class I dysfunction indicates loss of membraneous HLA class I staining
with preserved membraneous HLA class II and cytoplasmic HLA-DM. HLA class II
dysfunction refers to loss of HLA class II or loss of HLA-DM with preserved mem-
braneous HLA class I. HLA class I and II dysfunction indicates loss of membrane-
ous HLA class I combined with either loss of membraneous class II or loss of
HLA-DM
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HLA loci on chromosome 6p21.18,19 Both in cHL and DLBCL
recent studies indicate that mutations of B2M are a common
mechanism for HLA class I loss20,32,33 as B2M is required for
the stabilization of the HLA class I heavy chain. Decreased
HLA class II expression in DLBCL is believed to arise through
repression of the HLA locus by decreased expression of
CIITA.27,34-38 The mechanism behind this repression is unclear.
Although CIITA alterations are common in primary mediasti-
nal B-cell lymphoma and result in loss of CIITA39 mutations of
CIITA in DLBCL are infrequent (0–9%) and can only partially
explain the loss of HLA class II.32,40-43 In cHL, 15% of cases
harbor a translocation of CIITA, resulting in an incomplete
downregulation of HLA class II.44 In addition, we previously
found mutations in 2 out of 6 cHL cell lines.45 Whatever the
mechanism is, downregulation of HLA is probably a response
to continuous antitumor immune responses that increase over
time with emergence of antigenic peptides that are related to
malignant transformation or disease progression.
Another immune evasive mechanism that we found to be
frequent in cHL cases is retained localization of CLIP in the
antigen binding groove of HLA class II. In a previous publica-
tion it was shown that in three fresh cHL affected lymph node
cell suspensions cell surface HLA class II was not occupied by
antigenic peptides, but by the non-immunogenic CLIP.16 We
have now shown that this is caused by lack of expression of
HLA-DM. HLA-DO is another HLA accessory molecule that
counteracts HLA-DM, but we found no increased expression of
HLA-DO (results not shown). Interestingly, presentation of
CLIP by dendritic cells antagonizes Th1 polarization. Thus,
presentation of CLIP by Hodgkin tumor cells may contribute
Figure 3. Immunohistochemical staining patterns in formalin ﬁxed parafﬁn embedded diffuse large B-cell lymphoma tissue for HLA class I, B2M, HLA class II and HLA-DM.
(A and B) negative and positive membranous staining for HLA class I heavy chains. (C and D) negative and positive membranous staining for B2M. (E and F) negative and
positive membranous staining for HLA class II. (G and H) negative and positive cytoplasmic staining for HLA-DM. 40x.
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to the predominant Th2/Treg T-cell populations that are
known to directly surround these tumor cells.46
Loss of HLA in B-cell lymphoma has been shown to be
related to a decrease in number of tumor inﬁltrating lympho-
cytes and diminished interferon-gamma responses.18,21 Both in
cHL and DLBCL lack of membranous HLA class II expression
on tumor cells has been shown to be an independent adverse
prognostic factor.15,25,26 However, with the introduction of rit-
uximab the prognostic value of HLA class II in DLBCL has
become less clear.47 It was recently suggested that cytoplasmic
HLA class II conveys a worse prognosis when compared with
HLA class II membrane or HLA class II negative staining.28 In
our current cohort of DLBCL patients treated with R-CHOP,
there was no signiﬁcant difference in PFS between patients
with normal HLA expression and patients with (combined)
aberrant expression patterns.
Disrupted antigen presentation is expected to have impor-
tant implications for the efﬁcacy of checkpoint inhibitors.
Despite a high ORR in relapsed cHL treated with a checkpoint
inhibitor only 17% of patients achieve a complete remission.5
In relapsed DLBCL, checkpoint inhibition as monotherapy
shows modest efﬁcacy (ORR of 36%).6 However, checkpoint
inhibition appears more effective when applied as a consolida-
tion strategy (ORR 51%).8 Lack of HLA class I results in loss of
presentation of tumor derived neo-antigenic peptides and
makes the tumor cells unrecognizable to CD8C cytotoxic T-
cells. This implies that the rationale for using immune check-
point inhibitors might be restricted to HLA class I positive
cases. Loss of cell surface expression of HLA class II on the
tumor cells may not be a problem, as priming of antitumor
immune responses can also occur through professional antigen
presenting cells present in the micro-environment. However, in
melanoma response to a PD-1 inhibitor does depend on pres-
ence of HLA class II on the tumor cells.48 Since, aberrant HLA
expression is the most prevalent ﬁnding that potentially can
hamper the efﬁcacy of checkpoint inhibitors, future clinical tri-
als with checkpoint inhibitors should consider HLA expression,
both in lymphomas and other cancers.
In conclusion, the majority of cHL, DLBCL, PCNSL and pri-
mary testicular lymphoma show HLA expression that is incom-
patible with normal antigen presentation. The combined losses
of HLA class I and HLA class II represent the most frequent
mechanism of immune escape. Loss of HLA-DM resulting in
the loss of antigen presentation through HLA class II presents a
novel mechanism of immune escape in cHL and DLBCL. Our
data implicate the importance of taking HLA expression into
account when evaluating efﬁcacy of checkpoint inhibitors.
Materials and methods
Patients and tumor samples
Primary diagnostic FFPE tissue blocks of 389 cHL, 22 NLPHL,
137 DLBCL not otherwise speciﬁed 39 PCNSL and 19 primary
testicular lymphoma patients were retrieved from the tissue
banks of the pathology department of the University Medical
Center Groningen and afﬁliated hospitals between 1987 and
2011. Part of the HLA expression data in cHL (n D 292) was
described previously in relation to clinical outcome.15 In
addition, frozen tissue sections from 20 cHL patients included
in the cohort of 389 patients, were included. All cases were
reviewed by two experienced hematopathologists. To determine
the prognostic value of aberrant HLA expression in DLBCL
clinical data on the patients was retrieved from the electronic
hospital database of the University Medical Center Groningen.
The primary clinical end point was PFS, deﬁned as the time
from treatment until relapse or death. Follow-up was com-
pleted until December 2015. Patients were treated according to
best practice. IHC was performed on anonymized tissue sec-
tions in compliance with national ethical guidelines (“Code for
Proper Secondary Use of Human Tissue,” Dutch Federation of
Medical Scientiﬁc Societies) and the declaration of Helsinki.
Immunohistochemistry and scoring
Tissue sections of 3 mm were cut from formalin ﬁxed and
parafﬁn embedded tissue samples. Immunohistochemical
staining was performed according to standard procedures.
Brieﬂy, sections were dewaxed with xylene and endogenous
peroxidase was blocked. Antigen retrieval was performed in
10 mM Tris (tris-hydroxymethyl-aminomethane)/1 mM
EDTA (ethylene diamine tetracetic acid) at pH 9.0. Staining
was visualized with mouse mAbs HC10 (HLA class I heavy
chains, 1:500, kindly provided by Prof. Dr J. Neefjes, the
Netherlands Cancer Institute, Amsterdam), B2M (1:200,
DAKO, Glostrup, Denmark), HLA DR/DQ/DP (HLA class
II, 1:500, DAKO) and HLA-DM (1:200, BD Biosciences,
Breda, the Netherlands). Primary antibodies were detected
by secondary and tertiary conjugate antibodies. All cases
were stained for B2M, HLA class I and HLA class II. HLA-
DM staining was performed in all DLBCL and PCNSL cases
and in the cHL cases with membranous HLA class II expres-
sion. CLIP staining was performed on fresh frozen material
of 20 cHL patients with anti-CLIP (CerCLIP 1:200 BD) and
HLA-DM staining with anti HLA-DM (1:200 BD). For all
stainings, normal tonsil tissue was used as a positive control.
In the cHL cases, EBV status was determined by in situ
hybridization using a probe speciﬁc for EBV encoded RNAs
(EBERs). Scoring was performed by two experienced hema-
topathologists. Discrepant cases were subsequently discussed
until consensus was reached. For HLA class I and HLA class
II, membranous staining in the majority of tumor cells was
considered normal. Per case, HC10 and B2M were scored
consecutively and membranous staining was concordant for
all cases. For HLA-DM cytoplasmic staining was considered
as normal and for CLIP membranous staining was scored as
abnormal.
Statistical analysis
All categorical variables were expressed as percentages.
Where applicable, differences between groups were evaluated
by chi-square (for binary variables). A two-tailed p value of
less than 0.05 indicated statistical signiﬁcance. PFS curves
were estimated according to the Kaplan–Meier method.
Between-group differences in PFS were evaluated using the
log-rank test. All analyses were performed using IBM SPSS
Statistics version 22.
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